FDA warns Jubilant tablet plant in India for repeat mistakes

Pills in dollar sign (Photo: Eric Palmer)
Jubilant Life Sciences has been slapped by the FDA with a warning letter for one of its 14 plants in India. (Eric Palmer)

The FDA has picked apart the process of a Jubilant solid-dose plant in India and criticized it for repeating mistakes it had been told about in the past.

In a warning letter issued a week ago and just posted, the FDA said the Jubilant Life Sciences plant in Sikanderpur Bhainswal, Uttarakhand, had not thoroughly investigated customer complaints and that its quality-control lab was not testing every batch of a product when one batch failed testing, something management had previously committed to doing.

In one example, the letter said that the facility had received “numerous complaints for damage to functional coating on pantoprazole delayed release tablets” which could affect dissolution. Its investigation, however, tested tablets with discoloration instead of testing those with considerable enteric coating damage that were more likely to fail.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” the agency said, suggesting the company hire an outside consultant for help.

RELATED: India's Jubilant Life Sciences turns a manufacturing corner

These kinds of concerns are not new to the Indian company. Its sterile injectables plants in Spokane, Washington, and Kirkland, Canada, were cited with warning letters in 2013. The investigation of the Quebec plant was closed out the next year.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.